

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61L 29/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/28027</b> <b>(43) International Publication Date:</b> 2 July 1998 (02.07.98)
<b>(21) International Application Number:</b> PCT/GB97/03524 <b>(22) International Filing Date:</b> 23 December 1997 (23.12.97)  <b>(30) Priority Data:</b> 9626795.0 23 December 1996 (23.12.96) GB  <b>(71) Applicant (for all designated States except US):</b> ED GEISTLICH SOHNE AG FUR CHEMISCHE INDUSTRIE [CH/CH]; Bahnhofstrasse 40, CH-6110 Wolhusen (CH).  <b>(71) Applicant (for GB only):</b> PETT, Christopher [GB/GB]; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> LEHNER, Joachim, Hermann [DE/DE]; Scherrweg 5, D-44309 Dortmund (DE).  <b>(74) Agents:</b> PETT, Christopher et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).		<b>(81) Designated States:</b> CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> COMBATTING INFECTION IN DELIVERY SYSTEMS		
<b>(57) Abstract</b>		
<p>The use of taurolidine or taurultam in a method of combatting infection or sepsis in delivery systems is disclosed. In the method, taurolidine or taurultam solutions are used as a temporary seal or flush to prevent or reduce sepsis in delivery systems, such as port systems and/or catheters by which liquids are delivered into a patient.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

"Combating Infection in Delivery Systems"

5        This invention relates to a method for preventing  
and combating infection or sepsis in or caused by the  
use of delivery systems. More particularly it relates  
to a method for preventing bacterial colonisation in  
delivery systems which involve the use of catheters  
and/or reservoirs of liquid for infusions and the  
resultant sepsis in vivo. In particular it includes a  
10    method for reducing or substantially eliminating  
infection or sepsis in a subcutaneously-implanted access  
port for drug delivery either by arterial or venous  
access or peridural administration.

15        Delivery systems are widely used in medicine as a  
means for introducing liquid material which might  
include medicaments, nutrition, or other active agents  
to a particular locus in a patient. Such systems  
frequently involve the use of catheters which, for many  
20    applications, are surgically or intravenously located  
and stitched into place for long-term administration of  
the desired material. Typical systems include central  
catheters such as may be used for total parenteral  
nutrition (TPN) used in e.g. short bowel syndrome (for  
25    the duration of life), with the risk of sepsis or  
endocarditis, as well as catheters and drains which are  
involved in peritoneal dialysis for those with terminal  
kidney failure, which, if infected, can lead to  
peritonitis with serious consequences.

30        One type of delivery system used for some years in the  
treatment of conditions in humans comprises a reservoir  
or chamber of small volume subcutaneously-implanted  
under the fascia having direct access via a catheter to  
35    the cardiovascular system. Such systems are known as  
port systems.

Such systems are often used in the treatment of malignant conditions. The treatment of malignant conditions in humans is becoming increasingly sophisticated and the success rate is rising. Oncology has developed to the stage where particular medicaments or combinations of medicaments, e.g. combinations of cytostatics and metastasis inhibitors, in certain doses either as short or long term infusions or bolus injections can be successfully used to target particular types of malignancy and researchers have sought to develop ways by which regimes of chemotherapeutic medication, some of which can be highly toxic, can be administered to a patient at suitable dosage levels over a period of time. The use of i.v. infusion solutions and/or injections of anti-neoplastic agents can damage veins or cause severe complications such as spasm, paravasal necrosis, (thrombo)phlebitis and sepsis.

One type of reservoir includes a penetrable self-sealing membrane and can be filled or topped-up daily in vivo using a specially-designed syringe and needle. Such a reservoir allows slow continuous discharge of medication over a period of time at a dosage level that can be much more closely maintained and regulated than is the case with other forms of oral or parental administration. Because of the reduction in damage to the veins and discomfort of the patient, the technique clearly has a future but a complication which frequently occurs with serious results is that of infection and sepsis.

The reservoir and delivery system itself in this embodiment is usually implanted under local anaesthesia - below the collar bone in a small pocket created surgically on the fascia of the pectoral muscle is one site that has been used. Whilst all the normal precautions to prevent infection can be taken during implantation, it is in recharging of the device that

infection and sepsis is most likely to occur. The system is recharged using the syringe and needle which is passed through the skin and through the self-sealing but penetrable wall of the device. It is difficult to  
5 remove all bacteria on the skin prior to recharging and it is inevitable during recharge that some bacteria, for example nosocomial pathogens, and especially resistant pathogens e.g. MRSA or VRE, will be introduced into the system however meticulous the disinfection of the  
10 entrance point. Given that therapy is intended to be long-term and that such delivery systems are capable of being recharged up to 2,000 times, there is plenty of opportunity and time for bacterial or fungal infection to take seat and develop into an extremely serious  
15 condition. The most common infections are Staphylococcal, such as from multi-resistant *Staphylococcus aureus* (90% penicillin-resistant and methicillin and oxacillin resistant) (MRSA) or from vancomycin-resistant Enterococci (VRE) though other  
20 causative organisms such as Streptococci, and rare fungi such as *Pseudomonas* have also been reported. *Staphylococcus epidermidis* is probably the most frequently reported causative organism.

25 This situation is exacerbated by the nature of the drug treatment itself. Despite the advances that have been made, oncological chemotherapy still involves treating a patient with materials that are cytotoxic and long-term treatment of this type inevitably weakens the  
30 patient's immune system. Anti-neoplastic chemotherapy and radiotherapy lead to immunosuppression in patients. Immunosuppression in patients with malignant tumours leads to reduction of neutrophile granulocytes and neutropenia. Thus, at the same time as an infection may  
35 be building up in a patient, his immune system is less capable of dealing with it. The success of anti-neoplastic treatment therefore depends also on the

prophylaxis of nosocomial infections in these high-risk patients. Similar considerations apply to the use of such devices in administering medication for the treatment of AIDS.

5

Similar considerations can apply to other port systems. Other port systems are known for implantation in the arm, known as a peripheral venoid port catheter, for implantation in the peritoneum, for implantation in the hepatic artery and for spinal or epidural implantation.

10

It is estimated that such ports or catheter-based delivery systems give rise to infections in up to about 8% of cases. The frequency rate and fatality of sepsis does depend on the catheter site, and some of the risk can be reduced by suitable care of the entrance point. However, the consequences of sepsis are clearly dangerous and costly. Removal or replacement of the delivery system may well have to be carried out operatively, necessitating a further stay in hospital for the patient and further expense. The danger of general systemic infection is real and infection in the delivery system is difficult to treat with systemic antibiotics due to the minimal contact time they allow which is insufficient to combat the colonies of multi-resistant pathogens. In addition to this the possible intensive care costs are substantial. The treatment of a patient with severe sepsis can lead to problems such as ARDS (Adult Respiratory Distress Syndrome) necessitating polypragmasy and polypharmacy. The treatment of nosocomial pneumonia or endocarditis are particularly difficult.

15

20

25

30

Heart problems in particular can also be caused. If a cava catheter through which delivery of the medicament takes place is intubated into one of the veins returning to the heart, for example the cephalic or subclavian

35

vein, the femoral vein, one of the jugular veins or the basilic vein near the elbow, it is guided using X-ray during implantation so that the catheter tip is close to the point of entry of the vena cava into the heart. The heart is accordingly often one of the first organs likely to become colonised by bacteria, fungi or viruses and the feared endocarditis septica has been frequently reported. Other complications include vascular lesions, thrombosis, embolism or phlebitis.

Because the infection has its seat of colonised bacteria within the delivery system, this will not be removed simply by treating the patient systemically with antibiotics. Furthermore, attempts have been made to try and apply antibiotics to the delivery system itself, but this gives rise to difficulties because of the development of resistance problems and because of toxic reactions in the bloodstream which arise when the antibiotic is flushed out of the delivery system with isotonic salt solution. This can result in a toxic allergic bolus-type injection of antibiotics which, in severe cases, can result in anaphylactic shock.

In addition, apart from toxicity problems, a further problem once the delivery system is infected is the release by bacteria of bacterial toxins which result in deposit of a fibrin or collagen net on the internal surface of the delivery system. The net can act as support for the growth of residual resistant and untreatable bacteria leading to superinfection and colonisation by resistant pathogens. Fungi and viruses can also be present. Once this happens, the entire delivery system has to be removed immediately and replaced surgically elsewhere under anaesthetic.

Neither can antiseptics be used to rinse or seal the delivery system because they precipitate a toxic

reaction when they are ultimately flushed into the bloodstream. Since anything used to try to remove infection from the delivery system ultimately ends up passing intravenously into the body, the toxicity of general antiseptics completely rules them out of consideration.

We have now found that substantial advantages in the prevention and/or treatment of infection under these circumstances can be obtained if the delivery system is filled, flushed out or sealed when not in use with solutions containing the antibacterial compounds taurultam or taurolidine. These compounds are the only compounds which until now have worked satisfactorily.

These compounds are particularly effective in combating not only infecting bacteria but also in preventing the release of bacterial toxins and as well as inactivating any that may be present. The release of cytokines which activate the coagulation and fibrinolytic systems would be prevented. These compounds are methylol transfer agents and exert their antibacterial activity by reacting with the bacterial cell wall components and forming covalent bonds. Despite, therefore, the possibility of quite lengthy residence time in the delivery system, they have been found not to cause any build-up of resistance. This is not the case with other conventional antibiotics.

In the context of the present situation, this fact that these compounds avoid the development of any resistance is a huge advantage. A solution of taurultam or taurolidine can be used to seal the delivery system between each administration of desired liquid material, such as chemotherapeutic agent or nutrient, or after withdrawal of any blood sample from the reservoir. Should there be any period of time when it is desired



not to use the delivery system for administration of chemotherapeutic or other active or nutritional agent, such as is often the case during the cyclical delivery of chemotherapeutic agents or during total parenteral  
5 nutrition, the delivery system can be filled with a taurolidine or taurultam solution to act as an antimicrobial seal. Relatively small volumes (of the order of a few millilitres, e.g. approximately 3ml) of taurolidine or taurultam are required for this. A  
10 contact time of about one hour is desirably a minimum, though the seal can be retained for up to twelve hours or more. All of these activities can be carried out without any development of resistance or build up of bacterial toxins such as LPS and exotoxins by resident  
15 bacteria. Taurolidine solutions are well tolerated i.v., as there is no toxicity and no side effects have been observed.

Accordingly, viewed from one aspect, we provide the use  
20 of taurolidine or taurultam solutions as a temporary seal to prevent or reduce infection and sepsis associated with the use of a delivery system. This is of particular application to the use of catheters.

25 Viewed from another aspect, the invention comprises the use of taurolidine or taurultam solutions to reduce or prevent infections associated with the use of subcutaneously-implanted delivery systems. These are of particular application to systems which deliver  
30 medication from a reservoir via catheter into the cardiovascular system, such as might be used during chemotherapy.

35 A preferred solution will contain from 0.5 to 3% by weight of taurolidine, or from 1 to 7.5% by weight taurultam, advantageously 3 to 5%, depending on the solubility of the compound. Solutions containing from

1.0 to 2.0% taurolidine are preferred.

5 The solutions will generally be made up in sterile pyrogen-free water and may also contain, for example, inorganic or other salts or other components to render them isotonic. Parenterally acceptable polyols may, for example, also be present since these have been observed to increase the overall intravenous tolerance of taurolidine. Suitable polyols include carbohydrates, 10 e.g. hexoses such as glucose and fructose (or mixtures of these such as invert sugar), pentoses such as xylose or polysaccharides such as dextran or hydrolysed starch; glycerol and sugar alcohols such as sorbitol, mannitol or xylitol.

15 The concentration of the polyol can usefully be in the range 3 - 40% by weight. In the case of glucose, the concentration may be in the range 10 - 30% by weight, preferably 20%.

20 The solutions may also contain polyvinylpyrrolidone (PVP). This may be incorporated into the solutions at a concentration of, e.g. from 4 to 7% by weight. A solution containing 5% PVP is preferred. This assists 25 in solubilising the active substance and contributes also to the oncotic pressure of the solution. The molecular weight of the PVP should not be greater than 30,000 and is preferably less than 10,000, for example between 7000 and 9000. Kollidone 17 as sold by BASF is 30 relatively quickly resorbed and excreted renally.

35 The use of taurolidine or taurultam has not been found to give rise to any adverse side-reactions and there appear to be no compatibility problems with the plastic materials of which a delivery reservoir or catheter can be made. Indeed, the use of taurolidine appears to have the further advantage that it can reduce the

adhesiveness of fibrin deposits within a plastic delivery system, thus leading to a lower incidence of residual bacteria and infections.

5 Typical procedures, which should not be considered as limiting, are as follows:

10 1.) A patient has a Port delivery system comprising a polyurethane chamber of approx. 0.5 cm<sup>3</sup> volume mounted on a small titanium plate implanted in a small pocket in the pectoral muscle. The tip of a catheter of approx 0.3mm diameter leading from it has been intubated into one of the major veins and lies close to the point of entry of the vena cava into the right atrium of the heart. After implantation the chamber was flushed through with 2ml of a sterile 0.9% by weight sodium chloride solution containing 800 I.E. heparin.

20 The chamber is then filled with approximately 3ml of a 2% by weight Taurolin® (taurolidine) solution (injected into the chamber by special syringe) and the device sealed for up to 12 hours or until whenever chemotherapeutic administration is due.

25 Prior to introducing a cancer chemotherapeutic agent, for example, the taurolidine solution is rinsed into the bloodstream using saline. Cancer chemotherapeutic agent as desired is then injected into the chamber and is taken into the body over a period of time. Examples of possible such agents include the alkylating agents, such as numistin hydrochloride and cyclophosphamide; antimetabolites such as fluorouracil, cytarabine and methotrexate; anti-tumour antibiotics such as bleomycin sulphate, daunorubicin hydrochloride and idarubicin hydrochloride; alkaloids such as vincristine sulphate and cisplatin such as carboplatin. These agents are administered via the port system in different

formulations for several short-term and long-term infusions or for bolus injections.

5 After each treatment with medication, or after use of the chamber to withdraw a sample of venous blood, the delivery system is rinsed meticulously with 10 ml of a sterile 0.9% sodium chloride solution. 2 ml of a 2% Taurolin® solution are then introduced into the chamber and the needle removed. The port system is then  
10 effectively sealed against microbial infection. After being rinsed with saline, further medication may then be introduced when desired and the cycle repeated.

15 2.) A patient undergoing total parenteral nutrition is fitted with a central catheter by known techniques. Nutrition is delivered overnight whilst the patient is asleep but during the day the catheter is sealed with approximately 3ml of 2% taurolidine solution. Such an amount and concentration is effective to prevent  
20 catheter sepsis, has no side effects when it passes into the body when nutrition recommences possibly several hours later, and has clear advantages over the alternative procedure which involves using large volumes of antibacterial agents mixed with and administered  
25 along with the nutrient mix itself.

CLAIMS

1. The use of a solution of taurolidine or taurultam  
5 as a temporary seal or flush to prevent or reduce  
infection and sepsis in liquid delivery systems.
2. Use as claimed in claim 1 wherein the delivery  
system involves use of a catheter.
- 10 3. Use as claimed in claim 1 or claim 2 wherein the  
delivery system is a subcutaneously implanted delivery  
system, or port system.
- 15 4. Use as claimed in any of claims 1 to 3 wherein the  
solution contains from 0.5 to 3% by weight of  
taurolidine or from 1 to 7.5% by weight of taurultam.
- 20 5. A method of preventing or reducing infection and  
sepsis in a liquid delivery system which comprises  
filling, flushing out or temporarily sealing said system  
with a solution of taurolidine or taurultam.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/03524

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61L29/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MUGHAL M. ET AL.: "INFECTED FEEDING LINES" CARE OF THE CRITICALLY ILL, vol. 6, no. 6, 1990, pages 228-231, XP002062743 see page 230, right-hand column, paragraph 4 - page 231, left-hand column, paragraph 2	1,2,5
X	JOHNSTON D.A. ET AL.: "TAUROLIN FOR THE PREVENTION OF PARENTERAL NUTRITION RELATED INFECTION: ANTIMICROBIAL ACTIVITY AND LONG-TERM USE" CLINICAL NUTRITION, vol. 12, no. 6, 1993, pages 365-368, XP002062744 see abstract	1,2,4,5
	-/-	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 April 1998

Date of mailing of the international search report

08/05/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Heck, G

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/03524

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>           BLENKHARN J. I.: "THE ANTIMICROBIAL            ACTIVITY OF TAULOLIN - A POSSIBLE ADDITIVE            FOR PARENTERAL NUTRITION SOLUTIONS"            CLINICAL NUTRITION,            vol. 6, no. 1, 1987,            pages 35-38, XP002062745            see abstract            see page 37, left-hand column, paragraph 4            - right-hand column, paragraph 1            -----         </p>	1,2,5